



Name	Sungnam Lim	
Current Position	Associate Professor	
Country	Republic of Korea	
Major Field	Hematology	

Educational Background

- Mar. 1995-Feb. 2001: Ulsan University College of Medicine, Korea
Bachelor of Medicine
- Mar. 2007-Feb. 2008: Master of Medical Science (Internal Medicine)
University of Ulsan College of Medicine, Republic of Korea
- Mar. 2010-Feb. 2017: Ph.D. of Medical Science (Internal Medicine)
University of Ulsan College of Medicine, Korea

Professional Experience

- Mar. 2005-Feb. 2008: Internal Medicine, Asan Medical Center, Republic of Korea
Residency Training
- Mar. 2009-Apr. 2010: Department of Hematology, Asan Medical Center, Republic of Korea
Fellowship Training
- May 2010-Feb. 2014: Division of Hematology-Oncology, Department of Internal Medicine,
ChungBuk National University Hospital
Clinical Assistant Professor
- Mar. 2014 – Till date: Division of Hematology-Oncology, Department of Internal Medicine,
Haedae-Paik Hospital, College of Medicine, Inje University

Other Experience and Professional Memberships

- 2001 Korean Medical Association
- 2009 Korean Association of Internal Medicine
- 2011 Hematology-Oncology subspecialist (Korean Association of Internal Medicine)

Main Scientific Publications

1. The derived neutrophil-to-lymphocyte ratio is an independent prognostic factor in transplantation ineligible patients with multiple myeloma, *Acta Haematologica*, 2018;140:146-156
2. Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study, *Leukemia Research* 2018;60:135-144
3. Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy, *Ann Hematol.* 2018;96:1801-1809
4. Reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin for haematopoietic cell



-
- transplantation from unrelated or haploidentical family donors in patients with acute myeloid leukemia in remission, *bbmt*, 2017;23:1555-1566
5. Prospective randomized comparison of idarubicin and high-dose daunorubicin in induction chemotherapy for newly diagnosed acute myeloid leukemia, *J Clin Oncol*. 2017;35:2754-2763
 6. A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma, *Oncotarget* 2017;8:37605-37618
 - Tumor necrosis could reflect advanced disease status in patients with diffuse large B-cell lymphoma treated with R-CHOP therapy, *Ann Hematol*. 2017;96:17-23
 7. Tumor necrosis and complete resection has significant impacts on survival in patients with limited-stage upper aerodigestive tract NK/T cell lymphoma, *Oncotarget*, 2017;8:79337-79346
 8. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era, *Leukemia Research*, 2016;42:1-6
 9. A satisfaction survey on cancer pain management using a self-reporting pain assessment tool, *J Pall Medi*. 2015;18:225-231
 10. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia, *Blood* 2015;126:746-756
 11. Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia, *Am J Hematol*. 2015;90:1013-1020
 12. Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload, *Transfusion* 2015;55:1613-1620
 13. Impact of hyperglycemia on survival and infection-related adverse events in patients with metastatic colorectal cancer who were receiving palliative chemotherapy, *Cancer Res Treat*. 2014;46:288-296
 14. Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion, *Int. J Cancer* 2013;133:645-653
 15. Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms, *Blood Research* 2013;48:178-184
 16. Single nucleotide polymorphism of Wilms' tumor 1 gene rs16754 in Korean patients with cytogenetically normal acute myeloid leukemia, *Ann Hematology* 2012;91:671-677
 17. Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity, *Journal of Thoracic Oncology*, 2012;7:355-364
 18. Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine of myelodysplastic syndrome, *Leukemia Research* 2011;35:499-503
 19. Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia, *Leukemia Research* 2011;35:152-158
 - Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation, *Biol Blood Marrow Transplantation*, 2011;17:1222-1230
 20. Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome, *Leukemia research*, 2011;35:499-503
 21. Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia, *Lekemia research*, 2011;35:152-158
 22. Reevaluation of the national institutes of health criteria for classification and scoring of chronic GVHD, *Bone Marrow Transplantation*, 2010;45:1174-1180
 23. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity, *Bone Marrow Transplantation*, 2010;45:450-457
 24. Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia, *Leukemia Research*, 2009;33:511-5177
 25. Clinical significance of PML/RAR α isoforms in acute promyelocytic leukemia, *Korean Journal of Hematology*, 2008;75:412-419
 26. VPDL chemotherapy for T-cell lymphoblastic lymphoma (T-LBL) in adults: comparison with upfront autologous stem cell transplantation in a single center, *Korean Journal of Hematology*, 2008;43:138-144
-